J Epidemiol Community Health

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farmer, R. D.
Right arrow Articles by Tyrer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farmer, R. D.
Right arrow Articles by Tyrer, F.

Journal of Epidemiology and Community Health, Vol 51, 630-635


ARTICLES

Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives

RD Farmer, RB Newson, K MacRae, RA Lawrenson and F Tyrer
Department of Public Health and Primary Care, Charing Cross and Westminster Medical School, (University of London), Chelsea and Westminster Hospital.

STUDY OBJECTIVE: To investigate whether there has been an increase of venous thromboembolism (VTE) mortality in European countries, concurrent with the replacement of second generation by third generation combined oral contraceptives (COCs). Such an increase has been predicted, and reportedly detected, because published studies have detected an increased incidence of VTE associated with third generation rather than second generation COC use. DESIGN: Data were collected on population and annual VTE mortality in women 15-34 and 35-49 years old, and on second and third generation COC sales, from 1981 to 1994 in 13 European countries. Data from the seven most populous countries were analysed by linear regression of annual VTE mortality, in the 15-34 and 15-49 age groups, with respect to calculated total and third generation COC use rates, and the regression coefficients used to estimate mortality differences between second generation users and non-users and between third and second generation users, respectively. MAIN RESULTS: The estimated mortality differences in all seven countries had confidence intervals wide enough to contain both zero and the excess mortalities expected from the results of published studies. This was true both for the mortality difference between third and second generation COC users and for that between second generation users and COC non-users. CONCLUSIONS: Mortality differences of the size expected from the published studies cannot be measured using annual national VTE mortality and COC sales data alone, because of residual interannual variation in VTE mortality, and possibly confounding between rising third generation market share and total COC use.

 

Copyright © 1997 by the Journal of Epidemiology and Community Health


This article has been cited by other articles:


Home page
Body SocietyHome page
J. S. Hester
Bricolage and Bodies of Knowledge: Exploring Consumer Responses to Controversy about the Third Generation Oral Contraceptive Pill
Body Society, September 1, 2005; 11(3): 77 - 95.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1997 by the BMJ Publishing Group Ltd.